Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,164 matching trials from the live ClinicalTrials.gov search.
Conditions
Influenza
Interventions
Baloxavir, Placebos
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Springfield, Massachusetts • Cooperstown, New York • Portland, Oregon
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Inactivated Influenza Via Jet Injection

NCT02290691
Conditions
Influenza, Human
Interventions
Influenza Vaccine
Biological
Lead sponsor
PharmaJet, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
985 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Conditions
Influenza
Interventions
Pumarix™, Pandemrix ™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
780 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
7
States / cities
Huntsville, Alabama • Anaheim, California • Miami, Florida + 4 more
Conditions
Influenza
Interventions
Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
12 Months to 84 Months
Enrollment
607 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
19
States / cities
San Diego, California • San Gabriel, California • Colorado Springs, Colorado + 14 more
Conditions
Influenza
Interventions
Ear Loop Procedure Mask, 62% Ethyl Alcohol Hand Sanitizer
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1,420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Tetanus, diphtheria, and acellular pertussis vaccine, Pneumococcal polysaccharide vaccine, Seasonal influenza vaccine
Biological
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
29
States / cities
Palo Alto, California • Colorado Springs, Colorado • Southington, Connecticut + 26 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunology Study of a DNA Trivalent Influenza Vaccine

NCT00375206
Conditions
Influenza
Interventions
Trivalent DNA Vaccine (PIA0601) with or without DEI-LT (pPJV2012)
Biological
Lead sponsor
PowderMed
Industry
Eligibility
18 Years to 50 Years
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Lenexa, Kansas • Springfield, Missouri
Conditions
Influenza
Interventions
Reminder
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
139,503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Danville, Pennsylvania
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Jet Injection for Influenza

NCT01688921
Conditions
Influenza, Human
Interventions
AFLURIA vaccine (2012-2013 formulation), Needle-Syringe, Stratis needle-free injection device
Biological · Device
Lead sponsor
PharmaJet, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Fort Collins, Colorado • Loveland, Colorado
Conditions
Influenza
Interventions
Peramivir 150 mg, Peramivir 300 mg, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
58
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Anaheim, California + 45 more
Conditions
Influenza
Interventions
Baloxavir Marboxil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 1 Year
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Jonesboro, Arkansas • Tampa, Florida • Idaho Falls, Idaho + 5 more
Conditions
Neoplasms
Interventions
trivalent influenza vaccine
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Completed Not applicable Interventional Accepts healthy volunteers

Health Management Training to Enhance Influenza Vaccine Immunogenicity

NCT01256515
Conditions
No Conditions
Interventions
Health Education, Health Education Training
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

NCT07496450
Conditions
Influenza
Interventions
mRNA-1018-H5, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4,050 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
10
States / cities
San Bernardino, California • Savannah, Georgia • Meridian, Idaho + 7 more
Not listed Phase 4 Interventional Accepts healthy volunteers

Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks

NCT05012189
Conditions
Influenza, Influenza, Human, Influenza -Like Illness
Interventions
Oseltamivir, Baloxavir
Drug
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
18 Years to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Conditions
Influenza
Interventions
FluMist
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
5 Years to 49 Years
Enrollment
345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
11
States / cities
Miami, Florida • Chicago, Illinois • Bardstown, Kentucky + 8 more
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates

NCT07703514
Conditions
Influenza
Interventions
cH15/3, cH4/3, cH5/1N1, cH8/1N1, Saline
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Influenza
Interventions
AVI-7100, Placebo
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years

NCT00719043
Conditions
Influenza
Interventions
A/turkey H5N1 vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
841 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
10
States / cities
Denver, Colorado • Chicago, Illinois • Metairie, Louisiana + 7 more
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Response to Influenza Vaccine During Pregnancy

NCT03888989
Conditions
Influenza
Interventions
Quadrivalent inactivated influenza vaccine (IIV)
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Stanford, California
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Evaluating Immune Response to Seasonal FluMist in Healthy Adults

NCT01673425
Conditions
Influenza
Interventions
Live Attenuated Influenza Vaccine
Drug
Lead sponsor
National Center for Occupational Health and Infection Control
Federal
Eligibility
20 Years to 49 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Gainesville, Florida
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Parents in Appalachia Receive Education Needed for Teen Project

NCT01901770
Conditions
Healthy, Human Papilloma Virus Infection
Interventions
educational intervention
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
SARS-CoV-2, Influenza A, Influenza B, COVID-19
Interventions
LumiraDx SARS-CoV-2 Ag Ultra, LumiraDx SARS-CoV-2 & Flu A/B
Diagnostic Test
Lead sponsor
LumiraDx UK Limited
Industry
Eligibility
Not listed
Enrollment
716 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
10
States / cities
Garden Grove, California • Lomita, California • DeLand, Florida + 6 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels

NCT00944073
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 17 Years
Enrollment
583 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
9
States / cities
Baltimore, Maryland • Kansas City, Missouri • St Louis, Missouri + 6 more